Crossmark

A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis

Crossref DOI link: https://doi.org/10.1007/s10067-025-07597-4

Published Online: 2025-08-22

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Jiaqi

Yin, Xinbo

Kan, Xuewei

Yao, Pingping

Tang, Jun https://orcid.org/0009-0009-8156-4580
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82273516)
License Information

Text and Data Mining valid from 2025-08-22

Version of Record valid from 2025-08-22
More Information

Article History

Received: 2 January 2025

Revised: 1 July 2025

Accepted: 17 July 2025

First Online: 22 August 2025

Declarations

:

: No ethics approval was needed because data were retrieved from previously published studies in which informed consent was obtained by the primary investigators.

: None.

Document is current

Any future updates will be listed below